aldosterone and Abdominal Obesity studies

Research Excerpts

Excerpt	Relevance	Reference
"In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity."	9.24	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017)
"Aldosterone was not associated with IMMR, insulin sensitivity, or blood pressure and was unaffected by weight loss."	6.87	Aldosterone Is Not Associated With Metabolic and Microvascular Insulin Sensitivity in Abdominally Obese Men. ( de Leeuw, PW; Houben, AJHM; Joris, PJ; Kusters, YHAM; Mensink, RP; Plat, J; Schalkwijk, CG; Scheijen, JLJM; Schütten, MTJ; Stehouwer, CDA; van de Waarenburg, MPH, 2018)
"Increased abdominal obesity is associated with increased cardiovascular risk, especially in African American women."	6.82	Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. ( Bakris, GL; Laffin, LJ; Liao, C; Majewski, C, 2016)
"In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity."	5.24	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017)
"Aldosterone was not associated with IMMR, insulin sensitivity, or blood pressure and was unaffected by weight loss."	2.87	Aldosterone Is Not Associated With Metabolic and Microvascular Insulin Sensitivity in Abdominally Obese Men. ( de Leeuw, PW; Houben, AJHM; Joris, PJ; Kusters, YHAM; Mensink, RP; Plat, J; Schalkwijk, CG; Scheijen, JLJM; Schütten, MTJ; Stehouwer, CDA; van de Waarenburg, MPH, 2018)
"Increased abdominal obesity is associated with increased cardiovascular risk, especially in African American women."	2.82	Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. ( Bakris, GL; Laffin, LJ; Liao, C; Majewski, C, 2016)
"There is a strong association between abdominal obesity and circulating levels of aldosterone, and markers of abdominal obesity identify patients most likely to benefit from mineralocorticoid receptor antagonism."	2.58	Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. ( Packer, M, 2018)
"Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years."	1.42	Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. ( Bailey, KR; Buglioni, A; Burnett, JC; Cannone, V; Heublein, DM; Rodeheffer, RJ; Sangaralingham, SJ; Sarzani, R; Scott, CG, 2015)

Research

Studies (10)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Arterial Inflammation

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (80.00)	24.3611
2020's	2 (20.00)	2.80

Authors	Studies
Chen, KM	2
Chang, YL	1
Wu, TH	2
Lee, BC	2
Chen, PT	2
Liu, KL	2
Hong, JS	2
Chang, CC	2
Wu, VC	1
Lin, YH	2
Lin, KH	1
Schütten, MTJ	1
Kusters, YHAM	1
Houben, AJHM	1
Scheijen, JLJM	1
van de Waarenburg, MPH	1
Schalkwijk, CG	1
Joris, PJ	1
Plat, J	1
Mensink, RP	1
de Leeuw, PW	1
Stehouwer, CDA	1
Packer, M	1
Tarjus, A	1
Martínez-Martínez, E	1
Amador, C	1
Latouche, C	1
El Moghrabi, S	1
Berger, T	1
Mak, TW	1
Fay, R	1
Farman, N	1
Rossignol, P	2
Zannad, F	2
López-Andrés, N	1
Jaisser, F	1
Leopold, JA	1
Srinivasa, S	1
Fitch, KV	1
Wong, K	1
Torriani, M	1
Mayhew, C	1
Stanley, T	1
Lo, J	1
Adler, GK	1
Grinspoon, SK	1
Buglioni, A	1
Cannone, V	1
Sangaralingham, SJ	1
Heublein, DM	1
Scott, CG	1
Bailey, KR	1
Rodeheffer, RJ	1
Sarzani, R	1
Burnett, JC	1
Laffin, LJ	1
Majewski, C	1
Liao, C	1
Bakris, GL	1
Olivier, A	1
Pitt, B	1
Girerd, N	1
Lamiral, Z	1
Machu, JL	1
McMurray, JJV	1
Swedberg, K	1
van Veldhuisen, DJ	1
Collier, TJ	1
Pocock, SJ	1
Pizard, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Vascular Function Markers: Differences Between Lean and Abdominally Overweight / Obese Men and Effects of Weight Loss[NCT01675401]		75 participants (Actual)	Interventional	2012-09-30	Completed
Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study[NCT04153136]	Phase 2	50 participants (Anticipated)	Interventional	2020-09-11	Recruiting
Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study[NCT02740179]		40 participants (Actual)	Interventional	2017-01-31	Completed
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV[NCT01407237]		30 participants (Actual)	Observational	2012-01-31	Completed
A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095]		30 participants (Actual)	Interventional	2020-08-16	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Percentage change (value at 12 months minus value at baseline) in target to background ratio (a measure of arterial inflammation) of the index vessel measured via positron emission tomography/computed tomography (NCT02740179)
Timeframe: 12 Months

Assessment of Cardiac Diastolic Function Via Cardiac Imaging

Intervention	percentage change (Median)
Eplerenone	-12.4
Placebo	5.1

Change (value at 12 months minus value at baseline) in left ventricular end diastolic volume on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Assessment of Cardiac Structure by Left Ventricular Mass on Cardiac Imaging

Intervention	mL (Mean)
Eplerenone	-13
Placebo	10

Change (value at 12 months minus value at baseline) in left ventricular mass on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Assessment of Cardiac Systolic Function Via Cardiac Imaging

Intervention	g (Median)
Eplerenone	1
Placebo	9

Change (value at 12 months minus value at baseline) in global circumferential strain (GCS) on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Coronary Plaque

Intervention	percentage GCS (Median)
Eplerenone	-1.3
Placebo	2.3

Change (value at 12 months minus value at baseline) in coronary plaque measured via coronary computed tomography angiogram assessed by coronary calcium score Scale: minimum 0 to maximum no limit, higher score indicates more plaque (NCT02740179)
Timeframe: 12 Months

Markers of Arterial Inflammation

Intervention	score on a scale (Median)
Eplerenone	0
Placebo	5

Change (value at 12 months minus value at baseline) in plasma LpPLA2 (NCT02740179)
Timeframe: 12 Months

Markers of Fibrosis

Intervention	ng/mL (Median)
Eplerenone	3.0
Placebo	2.6

Change (value at 12 months minus value at baseline) in myocardial fibrosis measured by T1 (a signal intensity that measures fibrosis) via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Markers of Immune Activation MCP-1

Intervention	ms (Median)
Eplerenone	25
Placebo	1

Change (value at 12 months minus value at baseline) in plasma MCP-1 (NCT02740179)
Timeframe: 12 Months

Markers of Immune Activation sCD163

Intervention	pg/mL (Median)
Eplerenone	285
Placebo	292

Change (value at 12 months minus value at baseline) in plasma sCD163 (NCT02740179)
Timeframe: 12 Months

Markers of Subclinical Injury

Intervention	ng/mL (Median)
Eplerenone	-275
Placebo	-160

Change (value at 12 months minus value at baseline) in serum NT-proBNP (NCT02740179)
Timeframe: 12 Months

Markers of Systemic Inflammation hsCRP

Intervention	ng/L (Median)
Eplerenone	19.4
Placebo	2.8

Change (value at 12 months minus value at baseline) in plasma hsCRP (NCT02740179)
Timeframe: 12 Months

Markers of Systemic Inflammation hsIL-6

Intervention	ng/mL (Median)
Eplerenone	189
Placebo	591

Change (value at 12 months minus value at baseline) in plasma hsIL-6 (NCT02740179)
Timeframe: 12 Months

Markers of Vascular Dysfunction

Intervention	pg/mL (Median)
Eplerenone	-0.8
Placebo	0.2

Change (value at 12 months minus value at baseline) in serum hs-cTnT (NCT02740179)
Timeframe: 12 Months

Myocardial Inflammation

Intervention	ng/L (Median)
Eplerenone	0.00
Placebo	0.00

Change (value at 12 months minus value at baseline) in myocardial inflammation measured by extracellular mass index (a measure of the inflammation within the heart) via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Myocardial Perfusion by MRI

Intervention	g/m^2 (Median)
Eplerenone	0.9
Placebo	-0.7

Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by myocardial blood flow measured via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months

Myocardial Perfusion by PET

Intervention	mL/min/g (Mean)
Eplerenone	0.09
Placebo	-0.53

Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by coronary flow reserve measured via cardiac positron emission tomography. Coronary flow reserve is given by the ratio of blood flow at stress during maximal dilation of the coronary arteries to blood flow at rest. (NCT02740179)
Timeframe: 12 Months

Article	Year
Aldosterone-producing adenoma-harbouring KCNJ5 mutations is associated with lower prevalence of metabolic disorders and abdominal obesity. Journal of hypertension, 2021, 12-01, Volume: 39, Issue:12 Topics: Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Aldosterone; G Protein-Coupled Inwardly-Rectifying	2021
Evaluation of Abdominal Computed Tomography Scans for Differentiating the Discrepancies in Abdominal Adipose Tissue Between Two Major Subtypes of Primary Aldosteronism. Frontiers in endocrinology, 2021, Volume: 12 Topics: Abdominal Fat; Adult; Aged; Aldosterone; Databases, Factual; Essential Hypertension; Female; Humans;	2021
Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:1 Topics: Acute-Phase Proteins; Aldosterone; Animals; Aorta; Cardiomyopathy, Hypertrophic; Cells, Cultured; Cy	2015
The Central Role of Neutrophil Gelatinase-Associated Lipocalin in Cardiovascular Fibrosis. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 66, Issue:1 Topics: Acute-Phase Proteins; Aldosterone; Animals; Female; Humans; Lipocalins; Male; Obesity, Abdominal; On	2015
Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. Journal of the American Heart Association, 2015, Dec-23, Volume: 4, Issue:12 Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Echocardiography;	2015

aldosterone and Abdominal Obesity